18 papers in the library · 229 citations · publishing 2018-2025
Ther Adv Psychopharmacol December 4, 2025 Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al.
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Neuropharmacology December 1, 2025 Carina Joy Donegan, Dimitri Daldegan-Bueno, Tehseen Noorani et al. 4 citations
Expectations can impact antidepressant treatment and psychedelic therapy, often enhancing placebo effects and influencing outcomes. However, research in this context is lacking. Our study explored the expectations of participants with major depressive disorder (MDD) before microdosing lysergic acid diethylamide (LSD) in an open-label trial. Twenty-three individuals with MDD completed a...
Open MIND November 17, 2025 Dimitri Daldegan-Bueno, Suresh Muthukumaraswamy, Alana Cavadino
The analyses described in this SAP will assess the efficacy and safety of LSD (MB-22001) in comparison with active placebo (caffeine). The analysis described cover those for the primary, secondary and safety endpoints described in the Protocol.
Neuropharmacology November 5, 2025 Dimitri Daldegan-Bueno, C Donegan, Rachael Sumner et al. 4 citations
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various mental health disorders. This study evaluated the feasibility and tolerability of an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label phase 2A trial (LSDDEP1). Nineteen...
Journal of psychopharmacology (Oxford, England) June 28, 2025 Rafael S. Rodrigues, Isabel Wießner, Dimitri Daldegan-Bueno et al. 6 citations
This study aimed to validate and culturally adapt the Altered States of Consciousness Rating Scale (OAV) and Five Dimensional-Altered States of Consciousness Questionnaire (5D-ASC) for Brazilian Portuguese to measure altered states of consciousness in the context of psychedelic research. A parallel back-translation model was employed with expert reviews to ensure linguistic and cultural...
Brain Behavior and Immunity Integrative September 14, 2024 Bianca Castro Dos Santos, Ana Kéren Gomes Reis, Ricardo Aparecido Baptista Nucci et al. 1 citation
Neuropathic pain (NP), a debilitating and chronic condition often accompanied by comorbid depression, presents significant therapeutic challenges. While conventional pharmacological treatments, though valuable, usually fall short in addressing their multifaceted nature, the pursuit of innovative solutions has led to the exploration of ayahuasca , a psychedelic brew originating from Amazonian...
Trials August 24, 2024 Dimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth et al. 14 citations
Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable side effects. Classic psychedelics, including lysergic acid diethylamide (LSD), have garnered attention for their potential in treating psychiatric disorders. Microdosing, the repeated consumption of sub-hallucinogenic doses of psychedelics, has emerged...
Pilot and Feasibility Studies October 5, 2023 Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner et al. 23 citations
Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (LSD) and...
Progress in neuro-psychopharmacology & biological psychiatry July 13, 2023 Dimitri Daldegan-Bueno, Natalia Maria Simionato, Vanessa Manchim Favaro et al. 18 citations
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. Animal models are essential to investigate the pharmacological effects of ayahuasca since they can control important factors influencing it, such as the set and setting. Review and summarise data available on ayahuasca research using animal models. We systematically searched five databases (PubMed,...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology March 1, 2023 Isabel Wießner, Marcelo Falchi, Dimitri Daldegan-Bueno et al. 6 citations
Language has been explored as a window into the mind. Psychedelics, known to affect perception and cognition, seem to change language, but a systematic, time-dependent exploration is lacking. Therefore, we aimed at mapping the psychedelic effects on language over the time course of the acute and sub-acute effects in an explorative manner. For this, 24 healthy volunteers (age [mean±SD, range]:...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2023 Lucas Oliveira Maia, Dimitri Daldegan-Bueno, Isabel Wießner et al. 46 citations
The therapeutic potential of the psychedelic brew ayahuasca has been investigated in preclinical and clinical studies. Currently, the most consistent evidence refers to depression. However, various studies suggest that ayahuasca may comprise therapeutic benefits in other health conditions. This narrative review provides a comprehensive, up-to-date overview of ayahuasca's therapeutic effects in...
Substance Use & Misuse April 25, 2022 Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais et al. 15 citations
Background: Preliminary evidence suggests that long-term ayahuasca use is associated with better psychosocial outcomes and less drug use; however, available data on the association between ayahuasca intake frequency and psychosocial outcomes is limited. Objectives: We sought to characterize and investigate the association of regular ayahuasca use, as compared to non-regular use, on licit...
Behavioural Brain Research April 1, 2022 Dimitri Daldegan-Bueno, Vanessa Manchim Favaro, Paulo Rogério Morais et al. 10 citations
Considering the long-lasting effects of ayahuasca on the brain and emotional processing, the objective of this study was to evaluate the behavioural and neurobiological effects of repeated ayahuasca administration in an animal model of exploratory behaviour related to novel-environment anxiety. Male Wistar rats received water, 120, 240, 480 or 3600 mg/kg of resuspended freeze-dried ayahuasca by...
Psychopharmacology (Berl) February 18, 2022 Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti et al.
RationaleSmoking-related disease is a major problem globally. Effective smoking cessation treatments are however limited. Increasing evidence suggests that psychedelics have potential as treatments for substance use disorders and may therefore prove an option in aiding smoking cessation.ObjectivesTo establish which factors predict smoking cessation in people who reported quitting or reducing...
Journal of Psychopharmacology February 1, 2022 Isabel Wießner, Marcelo Falchi-Carvalho, Lucas Oliveira Maia et al. 43 citations
Background: Controversy surrounds psychedelics and their potential to boost creativity. To date, psychedelic studies lack a uniform conceptualization of creativity and methodologically rigorous designs. Aims: This study aimed at addressing previous issues by examining the effects of lysergic acid diethylamide (LSD) on creativity using multimodal tasks and multidimensional approaches. Methods:...
Journal of Psychoactive Drugs September 17, 2021 Dimitri Daldegan-Bueno, Vanessa Manchim Favaro, Luís Fernando Tófoli et al. 6 citations
Ayahuasca is a psychoactive brew from the decoction of different Amazonian plants, traditionally used in several cultures, religions, and rituals. Scientific studies with ayahuasca are rapidly increasing due to its subjective effects and therapeutic potential. Although ayahuasca is traditionally used in its liquid presentation, lyophilized (freeze-dried) ayahuasca is often used in scientific...
Journal of Psychoactive Drugs December 7, 2020 Lucas Oliveira Maia, Dimitri Daldegan-Bueno, Luís Fernando Tófoli 33 citations
Diseases that threaten life raise existential questions that can be a source of psychological distress. Studies with psychedelics demonstrate therapeutic effects for anxiety and depression associated with life-threatening illnesses. Ayahuasca has been proposed as a possible therapeutic agent in the treatment of psychiatric disorders. Preliminary studies suggest that ayahuasca could promote...
Revista dos Trabalhos de Iniciação Científica da UNICAMP December 13, 2018 Carolina Marcolino Massarentti, Luís Fernando Tófoli, Lucas Oliveira Maia et al.
A Ayahuasca é um psicodélico utilizado em um contexto ritualístico e por religiões sincréticas brasileiras. Os usuários relatam experiências como aparecimento de imagens visuais com olhos fechados, indução de um estado de introspecção e reflexão, indução de memórias, desencadeamento de emoções intensas, insights sobre preocupações pessoais e cura de males físicos e psicológico. Neste contexto,...